With the rise of global travel and climate change expanding the reach of mosquito-borne illnesses, chikungunya virus is an emerging concern—even for Canadian travelers. With the recent approval of IXCHIQ®, the first-ever single-dose vaccine for chikungunya, you now have a vital tool to help protect your patients against this debilitating disease.

‍

Why This Matters for Travelers ✈️

Chikungunya is a mosquito-borne viral disease found in over 110 countries, including popular travel destinations for Canadians in South America, the Caribbean, Asia, and Africa. With 75% of the global population at risk, travelers need protection now more than ever.

‍

The Impact of Chikungunya Infection 🦟

⚠️75% of infected individuals develop symptoms, including sudden onset of high fever and severe joint pain.

⚠️43% experience chronic joint pain, lasting months to years, significantly impacting quality of life.

‍

Who Should Consider IXCHIQ^®?

✅Travelers to Chikungunya-endemic areas (e.g., South America, the Caribbean, Asia, Africa)

✅Individuals with high exposure risks (e.g., frequent travelers, humanitarian aid workers)

✅Patients with pre-existing conditions (e.g., arthritis, weakened immune system) who may be at higher risk of severe complications

‍

Vaccine Benefits 💉

✔️Single-dose immunization for adults 18+
✔️98.9% seroresponse rate at 28 days post-vaccination

✔️long-lasting protection, with 96.3% sustained immunity at 6 months

‍

Learn More

📌 For additional resources and information on IXCHIQ^®, visit www.ixchiq.ca

‍